Personalized medicine in the treatment of epilepsy

Principal Investigator: Patrick Cossette, Jacques L. Michaud, Berge Minassian
Theme : Health
Competition : Genomics and Personalized Health
Status : Completed
Start : Apr. 1, 2013
End: Mar. 31, 2017
Budget : $10,833,759.00



New diagnostic test for epilepsy gives hope to patients with drug-resistant form of the disease

Epilepsy affects approximately three percent of Canadians. Unfortunately anti-epileptic drugs are ineffective in about one-third of patients, who have a drug-resistant form of the disease. This form of epilepsy is extremely expensive to treat, with costs reaching an estimated $1.7 billion in Canada in 2012. 

 

The goal of this project is to develop a pharmacogenomic tool for the more accurate diagnosis of various forms of epilepsy, particularly those that are drug resistant. This decision-support tool would improve the lives of patients by giving them access to diagnostic information in a timelier manner, aiding their decision about treatment options, and helping to prevent cognitive decline in children. Introducing this tool to the Canadian health care system represents potential savings of nearly $12 million per year.

 

To learn more about the genetic program research on epilepsy, click here (in French)

Co-applicants and End-users:

Guy Rouleau Université de Montréal
Stephen Scherer University of Toronto
Elsa Rossignol Université de Montréal
Danielle Andrade University of Toronto
Lionel Carmant Université de Montréal
Jean Lachaine Université de Montréal
Marie-Pierre Dubé Université de Montréal
Jong Rho University of Calgary
Anne-Marie Laberge Université de Montréal
Grant Mitchell Université de Montréal
Samuel F. Berkovic Genetic Commission of the International league against epilepsy
Steve White NIH Anti-epilectic drug discovery platform